- Home
- DSU vs CYRX Comparison
DSU vs CYRX Comparison
Compare DSU & CYRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DSU | CYRX |
|---|---|---|
| Founded | 1998 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 548.1M | 438.7M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | DSU | CYRX |
|---|---|---|
| Price | $10.28 | $9.78 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $12.83 |
| AVG Volume (30 Days) | 148.2K | ★ 574.8K |
| Earning Date | 01-01-0001 | 11-04-2025 |
| Dividend Yield | ★ 10.06% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.27 |
| Revenue | N/A | ★ $243,795,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $9.20 |
| P/E Ratio | ★ N/A | $7.76 |
| Revenue Growth | N/A | ★ 41.27 |
| 52 Week Low | $9.22 | $4.58 |
| 52 Week High | $11.40 | $11.44 |
Technical Indicators
Market Signals| Indicator | DSU | CYRX |
|---|---|---|
| Relative Strength Index (RSI) | 49.37 | 59.63 |
| Support Level | $10.22 | $9.06 |
| Resistance Level | $10.34 | $9.72 |
| Average True Range (ATR) | 0.07 | 0.43 |
| MACD | 0.01 | 0.12 |
| Stochastic Oscillator | 71.71 | 98.86 |
Price Performance
Historical ComparisonAbout DSU Blackrock Debt Strategies Fund Inc.
Blackrock Debt Strategies Fund Inc is a diversified, closed-end management investment company. Its investment objective is to provide current income by investing in a diversified portfolio of U.S. companies' debt instruments including corporate loans. The fund's secondary investment objective is to provide capital appreciation.
About CYRX CryoPort Inc.
CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. It operates in two reportable segments: Life Sciences Services and Life Sciences Products. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.